Reuters logo
BRIEF-Nymox reports additional positive data from fexapotide BPH phase 3 trial
November 29, 2016 / 3:41 PM / 10 months ago

BRIEF-Nymox reports additional positive data from fexapotide BPH phase 3 trial

Nov 29 (Reuters) - Nymox Pharmaceutical Corp :

* Nymox reports additional positive results from completed fexapotide BPH phase 3 studies showing significant early response and first-line efficacy

* New phase 3 results indicate that fexapotide in trials was highly efficacious for first-line treatment of BPH Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below